The companies collaborated to advance digital biomarkers for the detection & monitoring of neurological diseases incl. ALS
NeuraLight’s platform uses computer vision, AI, deep learning algorithms & ML to identify oculometric digital biomarkers to transform clinical development, diagnostics & precision medicine in neurology. The collaboration entails sharing & tracking patient data to advance the use of ALS digital biomarkers in a parallel study
NeuroSense is conducting a P-IIb (PARADIGM) trial to evaluate the efficacy of NeuroSense’s PrimeC for ALS. The effectiveness of NeuraLight’s system will be validated by assuring objectivity, reliability & repeatability in trials as well as reducing costs and friction
Ref: PRNewswire | Image: NeuroSense Therapeutics
